MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why PACB Stock surged +2.47% Today — RQD Quant Desk Flash
$2.90 +2.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.91
Pacific Biosciences of California Inc. (PACB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $901.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.91 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PACB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY PACB SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.6% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.33-25.8% Next Q
29
Q2 (-2Q)Grade E$1.73+22% Next Q
32
Q3 (-1Q)Grade E$2.11+37.4% Next Q
34
CurrentGrade D-$2.90-8.1% Hist 90D α
37
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PACB Turnaround Squeeze
While PACB currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.83) and Max Pain ($3.05) forces dealer call-delta covering toward $3.61.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PACB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PACB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PACB Stock surged +2.47% Today — RQD Quant Desk Flash
Pacific Biosciences of California Inc. (PACB) surged +2.47% to $2.90, trading at 77% of its 52-week range ($1.07 – $3.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 77% of its 52-week range ($1.07 – $3.44) with RSI-14 at 61.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 28.6% gross margin and $0 annual free cash flow.
Live PACB Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PACB)
- ✓Walkthrough of PACB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PACB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +82.39%📐 HORIZONTAL RANGE
2026-10-30O $2.75H $2.90L $2.41C $2.90VOL 13.73M
RES: $3.79SUP: $1.05SMA50: $1.83SMA200: $1.61
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PACB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PACB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PACB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PACB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PACB)
Health Care Rank #742 of 1016
⚔️ CTKB vs PACB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PACB vs. CTKB, NAUT, ALMR, LAB)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Pacific Biosciences of California Inc. (PACB) ranks #742 by composite RQD confidence (37/100, grade D-) and #376 by equity capitalization ($901.4M). Within this direct 5-issuer industry benchmark cohort, PACB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with PACB at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PACB
ACTIVE
Pacific Biosciences of California Inc. | D- | 37/100 | — | 28.6% | -35.0% | +2.47% | $901.4M | Benchmark Subject |
| CTKB Cytek Biosciences Inc. | D- | 41/100 | — | 51.8% | -12.7% | +2.61% | $818.9M | /ctkb-vs-pacb → |
| NAUT Nautilus Biotechnology Inc. | D- | 41/100 | — | — | -35.0% | -2.18% | $399.9M | /naut-vs-pacb → |
| ALMR Alamar Biosciences Inc. | D | 48/100 | — | — | — | -0.76% | $2.36B | /almr-vs-pacb → |
| LAB Standard BioTools Inc. | D- | 41/100 | — | 49.9% | -28.7% | +0.49% | $244.7M | /lab-vs-pacb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001299130In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pacific Biosciences of California Inc. (PACB) reported GAAP revenue of $160.0M (+3.9% vs. FY2024 revenue of $154.0M ) , GAAP net income of -$546.4M, operating cash flow of -$111.2M, and free cash flow of -$113.9M (+46.3% YoY). On the balance sheet, PACB closed FY2025 with $784.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $160.0M | -$546.4M | -$111.2M | -$113.9M | $784.1M | — |
| FY2024 (FY) | 2024-12-31 | $154.0M | -$309.9M | -$206.1M | -$212.2M | $1.26B | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$306.7M | -$259.2M | -$259.2M | — | — |
3. PACB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PACB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Pacific Biosciences of California Inc. (NASDAQ: PACB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.90 (+2.47% 1D, market cap $901.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PACB ranks #742 in composite RQD confidence.
How does PACB compare to CTKB and NAUT in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PACB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 28.6%, and ROIC of -35.0%. By comparison, CTKB (Cytek Biosciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $399.9M). Among the 5-stock peer group, PACB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PACB?
Per PACB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001299130), Pacific Biosciences of California Inc. generated $160.0M in revenue (+3.9% YoY), -$546.4M in net income, and -$113.9M in free cash flow against $784.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PACB trading relative to its 50-day, 200-day, and 52-week technical levels?
PACB last traded at $2.90 (+2.47% on volume of 11,974,007 shares), positioning the stock +58.47% above its 50-day simple moving average ($1.83) and +80.12% above its 200-day simple moving average ($1.61). Across its 52-week range of $1.07 to $3.44, PACB sits at the 77.2% percentile with a 14-day RSI of 61.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.54 to $3.26).
PACB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PACB stock moving today?
Why PACB Stock surged +2.47% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.